Dyslipidemia is a metabolic disorder characterized by abnormal blood lipid levels, including LDL cholesterol, HDL cholesterol, and triglycerides. It is often asymptomatic but is a major cardiovascular risk factor because persistent lipid abnormalities promote atherosclerosis and vascular events. Management includes lifestyle interventions and lipid-lowering therapies based on risk.
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
New research presented at the ERA Congress found DCCB blood pressure medications were associated with a 33% increased risk of major adverse kidney events in Type 2 diabetes patients also receiving RAS and SGLT2 inhibitors. A separate study revealed that diabetic nephropathy patients exhibit the most severe biochemical disturbances, including markedly elevated glycemic indices and significantly impaired renal function compared to other groups.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
Clinical studies demonstrate GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss when combined with lifestyle changes, with patients achieving mean reductions of 14.9% body weight over 68 weeks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07777003 |
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels |
NOT_YET_RECRUITING | PHASE1 |
| NCT07729553 |
Vitamin D Status and Lipid Profile in Obese Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | |
| NCT07715461 |
Effect of macaúba Oil Combined With Green Exercises |
NOT_YET_RECRUITING | NA |
| NCT07710261 |
Effects of Policosanol and Exercise on Fitness and Lipids in People With Elevated Blood Lipids |
NOT_YET_RECRUITING | NA |
| NCT07703371 |
Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome |
RECRUITING | NA |
| NCT07696403 |
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose |
NOT_YET_RECRUITING | NA |
| NCT07692438 |
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD |
RECRUITING | NA |
| NCT07691268 |
Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions |
COMPLETED | PHASE1 |
| NCT07685639 |
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study |
NOT_YET_RECRUITING | NA |
| NCT07682948 |
A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers |
RECRUITING | PHASE1 |
